Sangamo Therapeutics, Inc

Ownership Transactions Reported by 22 Insiders

Symbol
SGMO on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
501 Canal Blvd., Richmond, CA

There are no Buy or Sell transactions made by insiders since 11/22/2024

Sangamo Therapeutics, Inc executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Biogen Inc. 10%+ Owner $6.75M Sep 26, 2023
Sandy Macrae PRESIDENT, CEO AND DIRECTOR, Director $1.36M Oct 22, 2025
Nathalie Dubois-Stringfellow Svp Chief Development Officer $477K Oct 22, 2025
Scott Willoughby Svp, Chief Legal Officer, Secy $465K Oct 22, 2025
Prathyusha Duraibabu Principal Financial Officer $462K Oct 22, 2025
Amy Pooler Vp, Head Of Research $167K Aug 24, 2024
Nikunj Jain Principal Accounting Officer $163K Oct 22, 2025
Gregory D. Davis Head of Research & Technology $128K Oct 22, 2025
David Mark McClung EVP, Chief Operating Officer $81.2K Nov 25, 2023
Rolf Andrew Ramelmeier EVP, Technical Operations $65.5K May 25, 2023
Jason D. Fontenot SVP, Chief Scientific Officer $52.1K Nov 25, 2023
Parker H Stewart Director $51.8K Jun 12, 2025
Karen L. Smith Director $47K Jun 12, 2025
James R. Meyers Director $45.8K Jun 12, 2025
Robert Carey Director $45.8K Jun 12, 2025
Kenneth J. Hillan Director $45.8K Jun 12, 2025
John Markels Director $44.3K Jun 12, 2025
Courtney Beers Director $38K Jun 12, 2025
Margaret Horn Director $38K Jun 12, 2025
Robert J. Schott SVP, Head of Development $28.9K Feb 25, 2022
Joseph S. Zakrzewski Director $23.2K Feb 25, 2022
Saira Ramasastry Director $13.6K Feb 25, 2022

Recent Insider Transactions by Companies or Individuals for Sangamo Therapeutics, Inc

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.